MCID: GLL018
MIFTS: 59

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 20 36 54 6 42 15
Gallbladder Carcinoma 12 54 15 17 70
Malignant Neoplasm of Gallbladder 12 70 32
Gallbladder Neoplasm 12 17 70
Carcinoma of Gallbladder 12 6
Malignant Neoplasm of Gallbladder Localized 70
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 44
Gallbladder Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3121 DOID:4948
KEGG 36 H00047
ICD9CM 34 156.0
MeSH 44 D005706
ICD10 32 C23
UMLS 70 C0016978 C0153452 C0235782 more

Summaries for Gallbladder Cancer

MedlinePlus : 42 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to bile duct cancer and cholangiocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Sevoflurane and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include gallbladder, liver and lymph node.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

KEGG : 36 Gallbladder cancer (GBC) is a relatively uncommon neoplasm, however its prognosis is poor with less than a 5% 5-year survival rate. There are considerable geographic differences in its incidence and etiology. Two main pathways of GBC pathogenesis have been identified. The most common is associated with gallstones and chronic inflammation of the gallbladder, whereas a second, less frequent pathway is associated with a congenital abnormality of the pancreatic bile-duct junction, which is particularly common in Japan. TP53 inactivation has an important and early role in GBC associated with gallstones and chronic inflammation. Although KRAS mutations are rarely detected in GBC associated with gallstones, they are frequent and early events in tumors associated with congenital abnormality of the pancreatic bile-duct junction.

Wikipedia : 73 Gallbladder cancer is a relatively uncommon cancer, with an incidence of fewer than 2 cases per 100,000... more...

Related Diseases for Gallbladder Cancer

Diseases in the Gallbladder Cancer family:

Gallbladder Carcinoma in Situ

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 32.4 TP53 SMAD4 KRAS CTNNB1
2 cholangiocarcinoma 32.3 UCA1 TUG1 TP53 SMAD4 PIK3CA MALAT1
3 gallbladder disease 31.8 TP53 KRAS GCASPC CYTOR CTNNB1
4 adenoma 31.5 TP53 SMAD4 PIK3CA KRAS CTNNB1
5 intrahepatic cholangiocarcinoma 31.4 TUG1 TP53 SMAD4 KRAS CTNNB1 CCAT1
6 in situ carcinoma 31.3 TP53 PIK3CA CTNNB1
7 bladder cancer 31.2 UCA1 TUG1 TP53 PIK3CA MALAT1 KRAS
8 adenocarcinoma 31.2 TP53 SMAD4 PIK3CA MALAT1 KRAS CTNNB1
9 adenosquamous carcinoma 31.1 TP53 SMAD4 PIK3CA KRAS
10 squamous cell carcinoma 30.9 UCA1 TUG1 TP53 SMAD4 PIK3CA MALAT1
11 appendix adenocarcinoma 30.9 SMAD4 KRAS
12 carcinosarcoma 30.8 TP53 PIK3CA KRAS CTNNB1
13 thyroid carcinoma 30.7 UCA1 PIK3CA MALAT1 HOTAIR CDKN2B-AS1 AFAP1-AS1
14 embryonal sarcoma 30.6 TP53 MALAT1 CTNNB1
15 pseudomyxoma peritonei 30.6 TP53 KRAS CTNNB1
16 signet ring cell adenocarcinoma 30.6 TP53 KRAS CTNNB1
17 duodenum cancer 30.6 TP53 SMAD4 KRAS
18 rhabdomyosarcoma 30.6 TP53 SMAD4 PIK3CA KRAS CTNNB1
19 melanoma, uveal 30.5 TP53 SMAD4 PIK3CA MALAT1 CTNNB1
20 familial adenomatous polyposis 30.5 TP53 SMAD4 KRAS CTNNB1
21 gastric adenocarcinoma 30.5 TP53 SMAD4 PIK3CA KRAS HOTAIR CTNNB1
22 lynch syndrome 30.5 TP53 SMAD4 PIK3CA KRAS CTNNB1
23 ampulla of vater cancer 30.5 TP53 SMAD4 KRAS
24 myeloma, multiple 30.5 UCA1 TUG1 TP53 PIK3CA MALAT1 KRAS
25 lung cancer susceptibility 3 30.5 TUG1 TP53 SMAD4 PIK3CA NPTN-IT1 MALAT1
26 laryngeal squamous cell carcinoma 30.5 TP53 MALAT1 HOTAIR CDKN2B-AS1 CCAT1
27 sarcoma 30.5 TP53 PIK3CA KRAS ITGB1 HOTAIR CTNNB1
28 pancreatic ductal adenocarcinoma 30.5 UCA1 TP53 SMAD4 MALAT1 KRAS HOTAIR
29 kidney cancer 30.5 TP53 PIK3CA MALAT1 HOTAIR
30 glioma 30.5 UCA1 TP53 PIK3CA MALAT1 HOTAIR CYTOR
31 retinitis pigmentosa 11 30.4 UCA1 TP53 HOTAIR
32 renal cell carcinoma, nonpapillary 30.4 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MALAT1
33 pancreatic cancer 30.4 UCA1 TUG1 TP53 SMAD4 PIK3CA MALAT1
34 small cell cancer of the lung 30.4 TUG1 TP53 PIK3CA MALAT1 HOTAIR
35 nasopharyngeal carcinoma 30.4 TP53 SMAD4 PIK3CA NPTN-IT1 MALAT1 LINC-ROR
36 melanoma 30.3 UCA1 TP53 PIK3CA MALAT1 LINC-ROR KRAS
37 oral squamous cell carcinoma 30.3 UCA1 TUG1 TP53 MALAT1 HOTAIR CTNNB1
38 leukemia, acute myeloid 30.2 UCA1 TUG1 TP53 PIK3CA MALAT1 KRAS
39 ovarian cancer 30.0 UCA1 TUG1 TP53 SMAD4 PIK3CA MALAT1
40 lung cancer 29.9 UCA1 TUG1 TP53 SMAD4 PIK3CA MALAT1
41 gastric cancer 29.7 UCA1 TUG1 TP53 SMAD4 PIK3CA NPTN-IT1
42 adenosquamous gallbladder carcinoma 11.4
43 carcinoma of gallbladder and extrahepatic biliary tract 11.3
44 biliary tract cancer 11.1
45 gallbladder carcinoma in situ 11.1
46 gallbladder disease 1 10.9
47 cholecystitis 10.9
48 cholelithiasis 10.7
49 endometrioid ovary carcinoma 10.6 TP53 PIK3CA KRAS CTNNB1
50 female reproductive endometrioid cancer 10.6 TP53 PIK3CA KRAS CTNNB1

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Desflurane Approved Phase 4 57041-67-5 42113
3 Anesthetics Phase 4
4 Anesthetics, Inhalation Phase 4
5 Anesthetics, General Phase 4
6 Platelet Aggregation Inhibitors Phase 4
7 Ulipristal acetate Phase 4 126784-99-4
8
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
9
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
10
leucovorin Approved Phase 3 58-05-9 6006
11
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
12
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
13
Citalopram Approved Phase 3 59729-33-8 2771
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15
Dexetimide Withdrawn Phase 3 21888-98-2
16 Antiemetics Phase 3
17 Micronutrients Phase 3
18 Trace Elements Phase 3
19 Antidotes Phase 3
20 Nutrients Phase 3
21 Vitamin B Complex Phase 3
22 Folate Phase 3
23 Protective Agents Phase 3
24 Vitamins Phase 3
25 Vitamin B9 Phase 3
26 Antibiotics, Antitubercular Phase 3
27 Hormone Antagonists Phase 3
28 Anti-Bacterial Agents Phase 3
29 Emetics Phase 3
30 Hematinics Phase 3
31 Mitogens Phase 2, Phase 3
32 Cola Phase 3
33 Liver Extracts Phase 3
34 Neurotransmitter Agents Phase 3
35 Psychotropic Drugs Phase 3
36 Cholinergic Agents Phase 3
37 Serotonin Uptake Inhibitors Phase 3
38 Muscarinic Antagonists Phase 3
39 Antiparkinson Agents Phase 3
40 Cholinergic Antagonists Phase 3
41 Parasympatholytics Phase 3
42 Antidepressive Agents Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
45
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
46
Lenograstim Approved, Investigational Phase 2 135968-09-1
47
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
48
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Trametinib Approved Phase 2 871700-17-3 11707110

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
2 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
3 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
4 A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
5 Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial Completed NCT00391183 Phase 2, Phase 3
6 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
7 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
8 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
9 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
10 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
11 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
12 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
13 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
14 Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial Recruiting NCT04559139 Phase 2, Phase 3 Cisplatin;Gemcitabine Hydrochloride
15 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
16 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
17 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
18 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
19 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
20 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
21 Perioperative Chemotherapy Prior To and After Reoperation for Incidental Gallbladder Cancer - An International, Randomized Phase III Trial Withdrawn NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
22 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
23 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
24 A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Unknown status NCT03702491 Phase 2 Apatinib;Tegafur
25 A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Unknown status NCT02836847 Phase 2 GEMOX;Cetuximab;Trastuzumab;Gefitinib;Lapatinib;Everolimus;Sorafenib;Crizotinib
26 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
27 Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Unknown status NCT03607643 Phase 1, Phase 2 Cannabidiol;Bortezomib;Leucovorin;5-FU;Oxaliplatin;Bevacizumab;Irinotecan;Gemcitabine;Temozolomide
28 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
29 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
30 Phase II Study of Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil in Patients With Unresectable Biliary Tract Carcinomas Completed NCT01572324 Phase 2 Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
31 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
32 A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
33 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
34 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
35 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
36 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
37 A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors Completed NCT00003276 Phase 2 irinotecan hydrochloride
38 A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
39 A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder Completed NCT00075504 Phase 2 triapine;gemcitabine
40 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
41 A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
42 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
43 Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
44 A Feasibility Phase II Study of Gemcitabine With Docetaxel With Concurrent 3-D Conformal Radiation Plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2 Gemcitabine;Docetaxel
45 Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer Completed NCT01016639 Phase 1, Phase 2
46 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
47 A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
48 A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers Completed NCT01425879 Phase 2 Akt Inhibitor MK2206
49 Concurrent Chemo-radiation Using Tomotherapy Based IMRT in Locally Advanced Gallbladder and Pancreatic Cancers :A Phase II Study Completed NCT01118897 Phase 1, Phase 2
50 An Unicentric RCT About Novel Radiation Stent Versus Nitinol SEMS for Palliative Treatment of Malignant Biliary Stricture Completed NCT01320241 Phase 2

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

19
Gallbladder

MalaCards organs/tissues related to Gallbladder Cancer:

40
Liver, Lymph Node, Pancreas, Small Intestine, Endothelial, Colon, Lung

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 5375)
# Title Authors PMID Year
1
The Chile Biliary Longitudinal Study: A Gallstone Cohort. 42 61
33524121 2021
2
Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study. 42 61
33485332 2021
3
Survival analysis of patients with primary gallbladder cancer from 2010 to 2015: A retrospective study based on SEER data. 42 61
33019404 2020
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
5
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma. 54 61
20037816 2009
6
Expression of nm23, KAI1 and spiral computed tomography findings in primary gallbladder carcinoma. 54 61
19951590 2009
7
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. 54 61
18946757 2008
8
Heparanase and gallbladder cancer: new insights into understanding tumor growth and invasion. 61 54
18318817 2008
9
Heparanase expression in gallbladder carcinoma and its correlation to prognosis. 54 61
17524042 2008
10
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. 54 61
17384652 2007
11
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 61 54
17465213 2007
12
Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. 54 61
17287171 2007
13
Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. 61 54
18158568 2007
14
Potential role of N-myristoyltransferase in cancer. 54 61
16846646 2007
15
Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. 54 61
17260103 2007
16
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 61 54
16820886 2006
17
Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma. 61 54
16794394 2006
18
Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. 54 61
16039043 2006
19
[Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo]. 61 54
16784656 2006
20
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]. 61 54
16681930 2006
21
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. 54 61
16619549 2006
22
The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells. 61 54
16309194 2005
23
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. 54 61
15870882 2005
24
Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. 54 61
15821928 2005
25
Expression of homeodomain protein CDX2 in gallbladder carcinomas. 61 54
15645288 2005
26
Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. 54 61
15832413 2005
27
Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. 54 61
15655836 2005
28
An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. 54 61
15578423 2005
29
[Detection of bone marrow micrometastases in patients with gallbladder cancer]. 61 54
15743160 2004
30
Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. 54 61
15567755 2004
31
Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. 61 54
15573254 2004
32
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. 61 54
15460847 2004
33
[The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism]. 61 54
15312360 2004
34
Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. 61 54
18333072 2004
35
Potent inhibitor of N-myristoylation: a novel molecular target for cancer. 54 61
14633729 2003
36
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. 54 61
14527906 2003
37
Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. 61 54
12969785 2003
38
Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. 61 54
12692194 2003
39
Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. 54 61
12532418 2003
40
[Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. 54 61
12654182 2003
41
A case of gallbladder carcinoma diagnosed preoperatively by the detection of human telomerase reverse transcriptase mRNA in endoscopically obtained gallbladder bile. 61 54
12561014 2003
42
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. 61 54
12680166 2003
43
Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. 54 61
12469220 2003
44
[Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. 54 61
12611235 2002
45
Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. 54 61
12439941 2002
46
The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. 54 61
14607700 2002
47
Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). 61 54
12239600 2002
48
Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. 54 61
11986189 2002
49
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. 61 54
11677947 2001
50
MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. 61 54
11295067 2001

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6 (show all 35)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.5(TP53):c.713G>A (p.Cys238Tyr) SNV Pathogenic 182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
2 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Pathogenic 17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
3 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic 45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
4 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
5 SMAD4 NM_005359.6(SMAD4):c.1333C>T (p.Arg445Ter) SNV Pathogenic 24850 rs377767360 GRCh37: 18:48603032-48603032
GRCh38: 18:51076662-51076662
6 KRAS NM_004985.5(KRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic 12578 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
7 TP53 NM_000546.5(TP53):c.1024C>T (p.Arg342Ter) SNV Pathogenic 182970 rs730882029 GRCh37: 17:7574003-7574003
GRCh38: 17:7670685-7670685
8 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu) SNV Pathogenic 232497 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
9 TP53 NM_000546.5(TP53):c.376-2A>G SNV Likely pathogenic 186236 rs786202799 GRCh37: 17:7578556-7578556
GRCh38: 17:7675238-7675238
10 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
11 BRAF NM_004333.6(BRAF):c.1779_1780delinsGA (p.Asp594Asn) Indel Likely pathogenic 375948 rs1057519718 GRCh37: 7:140453155-140453156
GRCh38: 7:140753355-140753356
12 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
13 ERBB3 NM_001005915.1(ERBB3):c.310G>T (p.Val104Leu) SNV Likely pathogenic 376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
14 ERBB3 NM_001005915.1(ERBB3):c.310G>A (p.Val104Met) SNV Likely pathogenic 376410 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
15 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
16 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu) SNV Likely pathogenic 376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
17 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln) SNV Likely pathogenic 376607 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
18 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
19 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely pathogenic 177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
20 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
21 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
22 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
23 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
24 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely pathogenic 375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
25 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
26 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr) SNV Likely pathogenic 127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
27 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro) SNV Likely pathogenic 376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
28 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
29 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro) SNV Likely pathogenic 376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
30 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr) SNV Likely pathogenic 376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
31 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe) SNV Likely pathogenic 12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
32 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly) SNV Likely pathogenic 376649 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
33 TP53 NM_000546.6(TP53):c.841G>C SNV Likely pathogenic 376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
34 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Uncertain significance 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
35 BRAF NM_001374258.1(BRAF):c.1879G>A (p.Asp627Asn) SNV Uncertain significance 1064425 GRCh37: 7:140453176-140453176
GRCh38: 7:140753376-140753376

Cosmic variations for Gallbladder Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM91859716 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
2 COSM134614922 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
3 COSM87804005 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
4 COSM134990112 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 TP53 SMAD4 PIK3CA KRAS CTNNB1
2 12.61 TP53 SMAD4 PIK3CA KRAS ITGB1 CTNNB1
3
Show member pathways
12.55 TP53 PIK3CA KRAS ITGB1 CTNNB1
4
Show member pathways
12.49 TP53 SMAD4 PIK3CA KRAS ITGB1 CTNNB1
5
Show member pathways
12.41 TP53 PIK3CA KRAS ITGB1 CTNNB1
6 12.18 TP53 SMAD4 PIK3CA KRAS
7
Show member pathways
12.08 TP53 PIK3CA KRAS ITGB1 CTNNB1
8 12.03 TP53 SMAD4 KRAS CTNNB1
9 11.98 TP53 SMAD4 KRAS CTNNB1
10 11.91 SMAD4 PIK3CA KRAS CTNNB1
11 11.87 TP53 PIK3CA KRAS ITGB1 CTNNB1
12 11.82 TP53 PIK3CA KRAS CTNNB1
13 11.77 SMAD4 PIK3CA KRAS
14 11.72 TP53 PIK3CA ITGB1
15 11.64 PIK3CA ITGB1 CTNNB1
16 11.58 SMAD4 PIK3CA KRAS
17 11.57 TP53 PIK3CA KRAS
18 11.41 TP53 SMAD4 PIK3CA KRAS CTNNB1
19 11.02 SMAD4 KRAS CTNNB1
20 10 UCA1 TP53 LINC-ROR HOTAIR

GO Terms for Gallbladder Cancer

Biological processes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gastrulation with mouth forming second GO:0001702 8.96 CTNNB1 SMAD4
2 cytokine-mediated signaling pathway GO:0019221 8.92 ITGB1 KRAS PIK3CA TP53

Molecular functions related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 I-SMAD binding GO:0070411 8.96 SMAD4 CTNNB1
2 RNA polymerase II transcription factor binding GO:0001085 8.8 CTNNB1 SMAD4 TP53

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....